📰 ReutersReutersCodex · 实盘不做把握 6/10
北京时间·🕒 发布 06:12:33时区推断·⟳ 抓取 06:15:43·⚡ 决策 07-28 06:16:20 +37s·91.4 天前
波士顿科学披露全公司重组计划，拟优化供应链并削减成本
波士顿科学（BSX.US）计划投入税前7亿至8亿美元重组，目标到2029年底基本完成并实现约5亿美元年化费用节省，但节省大部分将再投入增长项目，短线利润增量不清晰。
📄 原文Reuters↗ 原文
Boston Scientific's (BSX.N) board has approved a new company-wide restructuring plan aimed at cutting costs and to bet…
不做 波士顿科学（BSX.US）
多年期重组计划不是短周期硬催化，节省到2029年才完全体现且大部分再投入增长；二季报临近，当前不在盘后为该消息单独建仓。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-27 · 扩散 medium · price-in 风险 medium ↗
关键理由
- 波士顿科学（BSX.US）计划投入税前7亿至8亿美元重组，目标到2029年底基本完成并实现约5亿美元年化费用节省，但节省大部分将再投入增长项目，短线利润增量不清晰。
- 事件发生在二季报披露前两天，投资者焦点仍在心脏器械组合表现，重组属于多年期成本结构调整而非即时订单、获批或指引上修。
主要风险
- 若7月29日财报同步给出更明确的利润率或EPS上修，需由财报新事件重新研判。
原文全文
展开原文 · 1,235 字
Boston Scientific's (BSX.N) board has approved a new company-wide restructuring plan aimed at cutting costs and to better position the company for future growth, the medical device maker said in a regulatory filing on Monday.
Here are some details:
The company said the plan, approved on July 21, will involve supply chain optimization, moving some production between factories and changing how the organization is structured.
The changes are expected to begin this year and be largely finished by the end of 2029.
Boston Scientific said the restructuring will lead to some job losses, even as it continues hiring in areas where it is growing and shifting resources to meet global market demand.
The company estimates the plan will cost between $700 million and $800 million before taxes, with $600 million to $700 million of that expected to be paid out in cash.
In return, Boston Scientific expects to reduce its annual expenses by about $500 million once the changes are fully in place.
Much of the money saved will be reinvested into growth initiatives, the company said.
Boston is expected to post second-quarter results on July 29 with investor focus on the performance of its heart device portfolio.
Here are some details:
The company said the plan, approved on July 21, will involve supply chain optimization, moving some production between factories and changing how the organization is structured.
The changes are expected to begin this year and be largely finished by the end of 2029.
Boston Scientific said the restructuring will lead to some job losses, even as it continues hiring in areas where it is growing and shifting resources to meet global market demand.
The company estimates the plan will cost between $700 million and $800 million before taxes, with $600 million to $700 million of that expected to be paid out in cash.
In return, Boston Scientific expects to reduce its annual expenses by about $500 million once the changes are fully in place.
Much of the money saved will be reinvested into growth initiatives, the company said.
Boston is expected to post second-quarter results on July 29 with investor focus on the performance of its heart device portfolio.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。